% alzhub.org library filter
% Source: https://alzhub.org/research?score_min=67&atag=monoclonal
% 71 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{yaari2025-40955720,
  author  = {Yaari, Roy and Holdridge, Karen C and Williamson, Melissa and Wessels, Alette M and Shcherbinin, Sergey and Kotari, Vikas and Reiman, Eric M and Tariot, Pierre N and others},
  title   = {{Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70662},
  pmid    = {40955720},
  url     = {https://doi.org/10.1002/alz.70662}
}

@article{tonegawakuji2025-40163534,
  author  = {Tonegawa-Kuji, R. and Hou, Y. and Hu, B. and Lorincz-Comi, N. and Pieper, A. A. and Tousi, B. and Leverenz, J. B. and Cheng, F.},
  title   = {{Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: A systematic review and meta-analysis}},
  journal = {PLoS medicine},
  year    = {2025},
  doi     = {10.1371/journal.pmed.1004568},
  pmid    = {40163534},
  url     = {https://doi.org/10.1371/journal.pmed.1004568}
}

@article{pascuallucas2025-41058018,
  author  = {Pascual-Lucas, M. and Lacosta, A. M. and Montañés, M. and Canudas, J. and Loscos, J. and Monleón, I. and Allué, J. A. and Sarasa, L. and others},
  title   = {{Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70776},
  pmid    = {41058018},
  url     = {https://doi.org/10.1002/alz.70776}
}

@article{asada2025-40302041,
  author  = {Asada, Takashi and Thanasopoulou, Angeliki and Delmar, Paul and Wojtowicz, Jakub and Smith, Janice and Yoshiyama, Yasumasa and Yokoi, Katsunori and Watanabe, Chigusa and others},
  title   = {{Japanese participant data from three gantenerumab trials in early Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70192},
  pmid    = {40302041},
  url     = {https://doi.org/10.1002/alz.70192}
}

@article{javed2026-42605139,
  author  = {Javed, Muhammad Nouman and Khan, Saim Mahmood and Mustafa, Smaher and Mujtaba, Amna and Amin, Hassaan and Azhar, Naveen and Hameed, Abdullah and Zayed, Alaa and others},
  title   = {{Gantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta-Analysis}},
  journal = {Brain and behavior},
  year    = {2026},
  doi     = {10.1002/brb3.71643},
  pmid    = {42605139},
  url     = {https://doi.org/10.1002/brb3.71643}
}

@article{salloway2025-40390253,
  author  = {Salloway, S. and Pain, A. and Lee, E. and Papka, M. and Ferguson, M. B. and Wang, H. and Hu, H. and Lu, M. and others},
  title   = {{TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70293},
  pmid    = {40390253},
  url     = {https://doi.org/10.1002/alz.70293}
}

@article{dantas2024-37978096,
  author  = {Dantas, J. M. and Mutarelli, A. and Navalha, D. D. P. and Dagostin, C. S. and Romeiro, P. H. C. L. and Felix, N. and Nogueira, A. and Batista, S. and others},
  title   = {{Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis}},
  journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology},
  year    = {2024},
  doi     = {10.1007/s10072-023-07194-w},
  pmid    = {37978096},
  url     = {https://doi.org/10.1007/s10072-023-07194-w}
}

@article{tariot2026-41579901,
  author  = {Tariot, Pierre N and Lopera, Francisco S and Ríos-Romenets, Silvia and Sink, Kaycee M and Giraldo-Chica, Margarita and Acosta-Baena, Natalia and Villegas, Gustavo and Espinosa, Alejandro and others},
  title   = {{Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial}},
  journal = {The Lancet. Neurology},
  year    = {2026},
  doi     = {10.1016/s1474-4422(25)00426-0},
  pmid    = {41579901},
  url     = {https://doi.org/10.1016/s1474-4422(25)00426-0}
}

@article{avgerinos2021-33831607,
  author  = {Avgerinos, K. I. and Ferrucci, L. and Kapogiannis, D.},
  title   = {{Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease}},
  journal = {Ageing research reviews},
  year    = {2021},
  doi     = {10.1016/j.arr.2021.101339},
  pmid    = {33831607},
  url     = {https://doi.org/10.1016/j.arr.2021.101339}
}

@article{qiao2024-38429615,
  author  = {Qiao, Y. and Gu, J. and Yu, M. and Chi, Y. and Ma, Y.},
  title   = {{Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis}},
  journal = {CNS drugs},
  year    = {2024},
  doi     = {10.1007/s40263-024-01067-2},
  pmid    = {38429615},
  url     = {https://doi.org/10.1007/s40263-024-01067-2}
}

@article{toda2024-39350371,
  author  = {Toda, Y. and Iwatsubo, T. and Nakamura, Y. and Matsuda, N. and Miyata, M. and Jin, M. and Chen, T. and Kuribayashi, K. and others},
  title   = {{Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2024},
  doi     = {10.14283/jpad.2024.106},
  pmid    = {39350371},
  url     = {https://doi.org/10.14283/jpad.2024.106}
}

@article{kutzsche2025-40324978,
  author  = {Kutzsche, J. and Cosma, N. C. and Kauselmann, G. and Fenski, F. and Bieniek, C. and Bujnicki, T. and Pils, M. and Bannach, O. and others},
  title   = {{Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial}},
  journal = {Nature communications},
  year    = {2025},
  doi     = {10.1038/s41467-025-59295-z},
  pmid    = {40324978},
  url     = {https://doi.org/10.1038/s41467-025-59295-z}
}

@article{menegazdealmeida2024-38879828,
  author  = {Menegaz de Almeida, A. and Leite, M. and Lopes, L. M. and Gomes Lima, P. and Siegloch Barros, M. L. and Rocha Pinheiro, S. and Í, Andrade and Viana, P. and others},
  title   = {{Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis}},
  journal = {Expert review of neurotherapeutics},
  year    = {2024},
  doi     = {10.1080/14737175.2024.2367016},
  pmid    = {38879828},
  url     = {https://doi.org/10.1080/14737175.2024.2367016}
}

@article{salloway2021-34155411,
  author  = {Salloway, S. and Farlow, M. and McDade, E. and Clifford, D. B. and Wang, G. and Llibre-Guerra, J. J. and Hitchcock, J. M. and Mills, S. L. and others},
  title   = {{A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease}},
  journal = {Nature medicine},
  year    = {2021},
  doi     = {10.1038/s41591-021-01369-8},
  pmid    = {34155411},
  url     = {https://doi.org/10.1038/s41591-021-01369-8}
}

@article{rashad2022-36611492,
  author  = {Rashad, A. and Rasool, A. and Shaheryar, M. and Sarfraz, A. and Sarfraz, Z. and Robles-Velasco, K. and Cherrez-Ojeda, I.},
  title   = {{Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials}},
  journal = {Healthcare (Basel, Switzerland)},
  year    = {2022},
  doi     = {10.3390/healthcare11010032},
  pmid    = {36611492},
  url     = {https://doi.org/10.3390/healthcare11010032}
}

@article{chen2024-38567735,
  author  = {Chen, T. and O'Gorman, J. and Castrillo-Viguera, C. and Rajagovindan, R. and Curiale, G. G. and Tian, Y. and Patel, D. and von Rosenstiel, P. and others},
  title   = {{Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2024},
  doi     = {10.1002/alz.13755},
  pmid    = {38567735},
  url     = {https://doi.org/10.1002/alz.13755}
}

@article{hsu2025-40316479,
  author  = {Hsu, C. W. and Hsu, T. W. and Kao, Y. C. and Lin, Y. H. and Thompson, T. and Carvalho, A. F. and Stubbs, B. and Tseng, P. T. and others},
  title   = {{The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100195},
  pmid    = {40316479},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100195}
}

@article{bateman2025-40120616,
  author  = {Bateman, Randall J and Li, Yan and McDade, Eric M and Llibre-Guerra, Jorge J and Clifford, David B and Atri, Alireza and Mills, Susan L and Santacruz, Anna M and others},
  title   = {{Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial}},
  journal = {The Lancet. Neurology},
  year    = {2025},
  doi     = {10.1016/s1474-4422(25)00024-9},
  pmid    = {40120616},
  url     = {https://doi.org/10.1016/s1474-4422(25)00024-9}
}

@article{perry2026-41689888,
  author  = {Perry, Richard and Kipps, Christopher and Martín, Maria Eugenia Soto and Bozzali, Marco and Logroscino, Giancarlo and Trafford, Sarah and Dhadda, Shobha and Kanekiyo, Michio and others},
  title   = {{Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2026},
  doi     = {10.1016/j.tjpad.2026.100507},
  pmid    = {41689888},
  url     = {https://doi.org/10.1016/j.tjpad.2026.100507}
}

@article{kehoe2021-34687634,
  author  = {Kehoe, Patrick Gavin and Turner, Nicholas and Howden, Beth and Jarutyte, Lina and Clegg, Shona Louise and Malone, Ian Brian and Barnes, Josephine and Nielsen, Casper and others},
  title   = {{Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial}},
  journal = {The Lancet. Neurology},
  year    = {2021},
  doi     = {10.1016/s1474-4422(21)00263-5},
  pmid    = {34687634},
  url     = {https://doi.org/10.1016/s1474-4422(21)00263-5}
}

@article{terao2025-40386876,
  author  = {Terao, Itsuki and Kodama, Wakako},
  title   = {{Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis}},
  journal = {Journal of psychopharmacology (Oxford, England)},
  year    = {2025},
  doi     = {10.1177/02698811251340901},
  pmid    = {40386876},
  url     = {https://doi.org/10.1177/02698811251340901}
}

@article{mcdade2022-36544184,
  author  = {McDade, E. and Cummings, J. L. and Dhadda, S. and Swanson, C. J. and Reyderman, L. and Kanekiyo, M. and Koyama, A. and Irizarry, M. and others},
  title   = {{Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study}},
  journal = {Alzheimer's research \& therapy},
  year    = {2022},
  doi     = {10.1186/s13195-022-01124-2},
  pmid    = {36544184},
  url     = {https://doi.org/10.1186/s13195-022-01124-2}
}

@article{wu2023-38017568,
  author  = {Wu, W. and Ji, Y. and Wang, Z. and Wu, X. and Li, J. and Gu, F. and Chen, Z.},
  title   = {{The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials}},
  journal = {European journal of medical research},
  year    = {2023},
  doi     = {10.1186/s40001-023-01512-w},
  pmid    = {38017568},
  url     = {https://doi.org/10.1186/s40001-023-01512-w}
}

@article{penninkilampi2017-28025724,
  author  = {Penninkilampi, R. and Brothers, H. M. and Eslick, G. D.},
  title   = {{Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis}},
  journal = {Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology},
  year    = {2017},
  doi     = {10.1007/s11481-016-9722-5},
  pmid    = {28025724},
  url     = {https://doi.org/10.1007/s11481-016-9722-5}
}

@article{shim2026-41352683,
  author  = {Shim, G. H. and Lau, E. C. Y. and Huynh, A. L. H. and Lu, C. Y. and Tan, E. C. K.},
  title   = {{Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis}},
  journal = {Ageing research reviews},
  year    = {2026},
  doi     = {10.1016/j.arr.2025.102981},
  pmid    = {41352683},
  url     = {https://doi.org/10.1016/j.arr.2025.102981}
}

@article{lowe2021-34585215,
  author  = {Lowe, S L and Evans, C Duggan and Shcherbinin, S and Cheng, Y-J and Willis, B A and Gueorguieva, I and Lo, A C and Fleisher, A S and others},
  title   = {{Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2021},
  doi     = {10.14283/jpad.2021.56},
  pmid    = {34585215},
  url     = {https://doi.org/10.14283/jpad.2021.56}
}

@article{chowdhury2023-37902139,
  author  = {Chowdhury, Selia and Chowdhury, Nurjahan Shipa},
  title   = {{Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review}},
  journal = {International journal of immunopathology and pharmacology},
  year    = {2023},
  doi     = {10.1177/03946320231209839},
  pmid    = {37902139},
  url     = {https://doi.org/10.1177/03946320231209839}
}

@article{mallinckrodt2023-36946443,
  author  = {Mallinckrodt, C and Tian, Y and Aisen, P S and Barkhof, F and Cohen, S and Dent, G and Hansson, O and Harrison, K and others},
  title   = {{Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2023},
  doi     = {10.14283/jpad.2023.6},
  pmid    = {36946443},
  url     = {https://doi.org/10.14283/jpad.2023.6}
}

@article{sperling2023-37458272,
  author  = {Sperling, R. A. and Donohue, M. C. and Raman, R. and Rafii, M. S. and Johnson, K. and Masters, C. L. and van Dyck, C. H. and Iwatsubo, T. and others},
  title   = {{Trial of Solanezumab in Preclinical Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2305032},
  pmid    = {37458272},
  url     = {https://doi.org/10.1056/nejmoa2305032}
}

@article{solopova2023-38086820,
  author  = {Solopova, E. and Romero-Fernandez, W. and Harmsen, H. and Ventura-Antunes, L. and Wang, E. and Shostak, A. and Maldonado, J. and Donahue, M. J. and others},
  title   = {{Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease}},
  journal = {Nature communications},
  year    = {2023},
  doi     = {10.1038/s41467-023-43933-5},
  pmid    = {38086820},
  url     = {https://doi.org/10.1038/s41467-023-43933-5}
}

@article{jeremic2023-37423541,
  author  = {Jeremic, D. and Navarro-López, J. D. and Jiménez-Díaz, L.},
  title   = {{Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis}},
  journal = {Ageing research reviews},
  year    = {2023},
  doi     = {10.1016/j.arr.2023.102012},
  pmid    = {37423541},
  url     = {https://doi.org/10.1016/j.arr.2023.102012}
}

@article{pereiradasilva2025-40692324,
  author  = {Pereira da Silva, A. M. and Falcão, L. and Virgilio, F. and Rodrigues Menezes, I. and Leite, M. and Farias, E. and Nascimento, M. and Lee Han, M. and others},
  title   = {{Efficacy and APOE ε4-stratified risk of donanemab in Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2025},
  doi     = {10.1177/13872877251361044},
  pmid    = {40692324},
  url     = {https://doi.org/10.1177/13872877251361044}
}

@article{ketter2017-28269765,
  author  = {Ketter, N. and Brashear, H. R. and Bogert, J. and Di, J. and Miaux, Y. and Gass, A. and Purcell, D. D. and Barkhof, F. and others},
  title   = {{Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2017},
  doi     = {10.3233/jad-160216},
  pmid    = {28269765},
  url     = {https://doi.org/10.3233/jad-160216}
}

@article{salloway2018-30129411,
  author  = {Salloway, S. and Marshall, G. A. and Lu, M. and Brashear, H. R.},
  title   = {{Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study}},
  journal = {Current Alzheimer research},
  year    = {2018},
  doi     = {10.2174/1567205015666180821114813},
  pmid    = {30129411},
  url     = {https://doi.org/10.2174/1567205015666180821114813}
}

@article{neve2024-39177596,
  author  = {Neve, A. and Das, B. and Wojtowicz, J. and Huang, Z. and Bullain, S. and Watkin, M. and Lott, D. and Bittner, T. and others},
  title   = {{Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2024},
  doi     = {10.3233/jad-240221},
  pmid    = {39177596},
  url     = {https://doi.org/10.3233/jad-240221}
}

@article{boess2024-38706270,
  author  = {Boess, F G and Scelsi, M A and Grimmer, T and Perry, R J and Tonietto, M and Klein, G and Hofmann, C and Salami, M and others},
  title   = {{At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2024},
  doi     = {10.14283/jpad.2024.60},
  pmid    = {38706270},
  url     = {https://doi.org/10.14283/jpad.2024.60}
}

@article{farlow2012-22672770,
  author  = {Farlow, M. and Arnold, S. E. and van Dyck, C. H. and Aisen, P. S. and Snider, B. J. and Porsteinsson, A. P. and Friedrich, S. and Dean, R. A. and others},
  title   = {{Safety and biomarker effects of solanezumab in patients with Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2012},
  doi     = {10.1016/j.jalz.2011.09.224},
  pmid    = {22672770},
  url     = {https://doi.org/10.1016/j.jalz.2011.09.224}
}

@article{qiao2023-37213538,
  author  = {Qiao, Y. and Chi, Y. and Zhang, Q. and Ma, Y.},
  title   = {{Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials}},
  journal = {Frontiers in aging neuroscience},
  year    = {2023},
  doi     = {10.3389/fnagi.2023.1169499},
  pmid    = {37213538},
  url     = {https://doi.org/10.3389/fnagi.2023.1169499}
}

@article{hossain2024-38867460,
  author  = {Hossain, M. F. and Husna, A. U. and Kharel, M.},
  title   = {{Use of lecanemab for the treatment of Alzheimer's disease: A systematic review}},
  journal = {Brain and behavior},
  year    = {2024},
  doi     = {10.1002/brb3.3592},
  pmid    = {38867460},
  url     = {https://doi.org/10.1002/brb3.3592}
}

@article{relkin2017-28381506,
  author  = {Relkin, Norman R and Thomas, Ronald G and Rissman, Robert A and Brewer, James B and Rafii, Michael S and van Dyck, Christopher H and Jack, Clifford R and Sano, Mary and others},
  title   = {{A phase 3 trial of IV immunoglobulin for Alzheimer disease}},
  journal = {Neurology},
  year    = {2017},
  doi     = {10.1212/wnl.0000000000003904},
  pmid    = {28381506},
  url     = {https://doi.org/10.1212/wnl.0000000000003904}
}

@article{raket2026-42273802,
  author  = {Raket, Lars L and Lu, Ming and Evans, Cynthia D and Zimmer, Jennifer A and Sparks, JonDavid and Collins, Emily C and Shcherbinin, Sergey and Wang, Hong and others},
  title   = {{Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2026},
  doi     = {10.1002/alz.71577},
  pmid    = {42273802},
  url     = {https://doi.org/10.1002/alz.71577}
}

@article{cohen2023-37874099,
  author  = {Cohen, S and van Dyck, C H and Gee, M and Doherty, T and Kanekiyo, M and Dhadda, S and Li, D and Hersch, S and others},
  title   = {{Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2023},
  doi     = {10.14283/jpad.2023.123},
  pmid    = {37874099},
  url     = {https://doi.org/10.14283/jpad.2023.123}
}

@article{ackley2021-33632704,
  author  = {Ackley, S. F. and Zimmerman, S. C. and Brenowitz, W. D. and Tchetgen Tchetgen, E. J. and Gold, A. L. and Manly, J. J. and Mayeda, E. R. and Filshtein, T. J. and others},
  title   = {{Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis}},
  journal = {BMJ (Clinical research ed.)},
  year    = {2021},
  doi     = {10.1136/bmj.n156},
  pmid    = {33632704},
  url     = {https://doi.org/10.1136/bmj.n156}
}

@article{delnomdedieu2016-26925577,
  author  = {Delnomdedieu, M. and Duvvuri, S. and Li, D. J. and Atassi, N. and Lu, M. and Brashear, H. R. and Liu, E. and Ness, S. and others},
  title   = {{First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2016},
  doi     = {10.1186/s13195-016-0177-y},
  pmid    = {26925577},
  url     = {https://doi.org/10.1186/s13195-016-0177-y}
}

@article{chen2025-41070709,
  author  = {Chen, S. and Ou, R. and Wei, Q. and Li, C. and Song, W. and Zhao, B. and Yang, J. and Fu, J. and others},
  title   = {{Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70750},
  pmid    = {41070709},
  url     = {https://doi.org/10.1002/alz.70750}
}

@article{mccullough2025-40660741,
  author  = {McCullough, Austin and Chen, Charles D and Gordon, Brian A and Joseph-Mathurin, Nelly and Jack, Clifford R and Koeppe, Robert and Hornbeck, Russ and Koudelis, Deborah and others},
  title   = {{Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70347},
  pmid    = {40660741},
  url     = {https://doi.org/10.1002/alz.70347}
}

@article{holdridge2023-36946603,
  author  = {Holdridge, Karen C and Yaari, Roy and Hoban, Deirdre B and Andersen, Scott and Sims, John R},
  title   = {{Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2023},
  doi     = {10.1002/alz.13031},
  pmid    = {36946603},
  url     = {https://doi.org/10.1002/alz.13031}
}

@article{risner2006-16446752,
  author  = {Risner, M. E. and Saunders, A. M. and Altman, J. F. and Ormandy, G. C. and Craft, S. and Foley, I. M. and Zvartau-Hind, M. E. and Hosford, D. A. and others},
  title   = {{Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease}},
  journal = {The pharmacogenomics journal},
  year    = {2006},
  doi     = {10.1038/sj.tpj.6500369},
  pmid    = {16446752},
  url     = {https://doi.org/10.1038/sj.tpj.6500369}
}

@article{avgerinos2024-39468148,
  author  = {Avgerinos, K. I. and Manolopoulos, A. and Ferrucci, L. and Kapogiannis, D.},
  title   = {{Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness}},
  journal = {Scientific reports},
  year    = {2024},
  doi     = {10.1038/s41598-024-75204-8},
  pmid    = {39468148},
  url     = {https://doi.org/10.1038/s41598-024-75204-8}
}

@article{wang2025-40308765,
  author  = {Wang, H. and Pan, J. and Zhang, M. and Tan, Z.},
  title   = {{Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease}},
  journal = {Frontiers in pharmacology},
  year    = {2025},
  doi     = {10.3389/fphar.2025.1599048},
  pmid    = {40308765},
  url     = {https://doi.org/10.3389/fphar.2025.1599048}
}

@article{salloway2018-29914022,
  author  = {Salloway, S. P. and Sperling, R. and Fox, N. C. and Sabbagh, M. N. and Honig, L. S. and Porsteinsson, A. P. and Rofael, H. and Ketter, N. and others},
  title   = {{Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2018},
  doi     = {10.3233/jad-171157},
  pmid    = {29914022},
  url     = {https://doi.org/10.3233/jad-171157}
}

@article{abdelazim2024-38565747,
  author  = {Abdelazim, K. and Allam, A. A. and Afifi, B. and Abdulazeem, H. and Elbehiry, A. I.},
  title   = {{The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials}},
  journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology},
  year    = {2024},
  doi     = {10.1007/s10072-024-07477-w},
  pmid    = {38565747},
  url     = {https://doi.org/10.1007/s10072-024-07477-w}
}

@article{chundu2025-40621323,
  author  = {Chundu, U. C. and Thiriveedhi, SR. and Bhatti, C. and Mupparaju, J. S. and Otinashvili, N. and Gelishvili, E.},
  title   = {{A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease}},
  journal = {Cureus},
  year    = {2025},
  doi     = {10.7759/cureus.85377},
  pmid    = {40621323},
  url     = {https://doi.org/10.7759/cureus.85377}
}

@article{noguchishinohara2025-41276859,
  author  = {Noguchi-Shinohara, M. and Yoshinobu, T. and Ozaki, T. and Muramatsu, D. and Shima, A. and Sakashita, Y. and Tada, Y. and Yamaguchi, H. and others},
  title   = {{Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data}},
  journal = {Alzheimer's research \& therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01912-6},
  pmid    = {41276859},
  url     = {https://doi.org/10.1186/s13195-025-01912-6}
}

@article{hock2003-12765607,
  author  = {Hock, C. and Konietzko, U. and Streffer, JR. and Tracy, J. and Signorell, A. and Müller-Tillmanns, B. and Lemke, U. and Henke, K. and others},
  title   = {{Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease}},
  journal = {Neuron},
  year    = {2003},
  doi     = {10.1016/s0896-6273(03)00294-0},
  pmid    = {12765607},
  url     = {https://doi.org/10.1016/s0896-6273(03)00294-0}
}

@article{lacorte2022-35275549,
  author  = {Lacorte, E. and Ancidoni, A. and Zaccaria, V. and Remoli, G. and Tariciotti, L. and Bellomo, G. and Sciancalepore, F. and Corbo, M. and others},
  title   = {{Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2022},
  doi     = {10.3233/jad-220046},
  pmid    = {35275549},
  url     = {https://doi.org/10.3233/jad-220046}
}

@article{villain2022-36184326,
  author  = {Villain, N. and Planche, V. and Levy, R.},
  title   = {{High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects}},
  journal = {Revue neurologique},
  year    = {2022},
  doi     = {10.1016/j.neurol.2022.06.012},
  pmid    = {36184326},
  url     = {https://doi.org/10.1016/j.neurol.2022.06.012}
}

@article{knopman2023-37295957,
  author  = {Knopman, D. S. and Hershey, L.},
  title   = {{Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207438},
  pmid    = {37295957},
  url     = {https://doi.org/10.1212/wnl.0000000000207438}
}

@article{bregman2025-40437535,
  author  = {Bregman, N. and Nathan, T. and Shir, D. and Omer, N. and Levy, M. H. and David, A. B. and Aizenstien, O. and Lotan, E. and others},
  title   = {{Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01763-1},
  pmid    = {40437535},
  url     = {https://doi.org/10.1186/s13195-025-01763-1}
}

@article{chhabra2024-39432414,
  author  = {Chhabra, Akanksha and Solanki, Siddhant and Saravanabawan, Prithvi and Venkiteswaran, Arun and Nimmathota, NagaTarang and Modi, Nishi Manojkumar},
  title   = {{A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease}},
  journal = {Expert opinion on biological therapy},
  year    = {2024},
  doi     = {10.1080/14712598.2024.2416947},
  pmid    = {39432414},
  url     = {https://doi.org/10.1080/14712598.2024.2416947}
}

@article{su2025-40473116,
  author  = {Su, Ching-Hui and Chang, Ying-Tzu and Tseng, Huan-Shu and Kuo, Chan-Yen and Chen, Jin-Hua and Chien, Po-Yu and Chang, Yao-Jen and Hung, Chin-Chuan},
  title   = {{Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials}},
  journal = {Clinical medicine (London, England)},
  year    = {2025},
  doi     = {10.1016/j.clinme.2025.100336},
  pmid    = {40473116},
  url     = {https://doi.org/10.1016/j.clinme.2025.100336}
}

@article{dodel2025-40790925,
  author  = {Dodel, Richard and Frölich, Lutz},
  title   = {{Donanemab for Alzheimer's disease: from preclinical research to the clinical application}},
  journal = {Expert review of neurotherapeutics},
  year    = {2025},
  doi     = {10.1080/14737175.2025.2546868},
  pmid    = {40790925},
  url     = {https://doi.org/10.1080/14737175.2025.2546868}
}

@article{siemers2016-26238576,
  author  = {Siemers, E. R. and Sundell, K. L. and Carlson, C. and Case, M. and Sethuraman, G. and Liu-Seifert, H. and Dowsett, S. A. and Pontecorvo, M. J. and others},
  title   = {{Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2016},
  doi     = {10.1016/j.jalz.2015.06.1893},
  pmid    = {26238576},
  url     = {https://doi.org/10.1016/j.jalz.2015.06.1893}
}

@article{rahman2023-36775284,
  author  = {Rahman, Afroza and Hossen, Md Anwar and Chowdhury, Mirza Farhana Iqbal and Bari, Sadia and Tamanna, Nuzhat and Sultana, Syeda Salima and Haque, Sharar Naiarin and Masud, Abdullah Al and others},
  title   = {{Aducanumab for the treatment of Alzheimer's disease: a systematic review}},
  journal = {Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society},
  year    = {2023},
  doi     = {10.1111/psyg.12944},
  pmid    = {36775284},
  url     = {https://doi.org/10.1111/psyg.12944}
}

@article{shang2025-41250246,
  author  = {Shang, Jia and Zhong, Siyan and Shang, Li and Zeng, Qingze and Zhao, Shuai and Luo, Xiao and Li, Kaicheng and Zhang, Xinyi and others},
  title   = {{Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis}},
  journal = {Alzheimer's research \& therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01886-5},
  pmid    = {41250246},
  url     = {https://doi.org/10.1186/s13195-025-01886-5}
}

@article{shimasaki2026-41936348,
  author  = {Shimasaki, Ryosuke and Kurihara, Masanori and Bannai, Taro and Hatano, Keiko and Suzuki, Fumio and Tokumaru, Aya Midori and Ishii, Kenji and Ihara, Ryoko and others},
  title   = {{Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2026},
  doi     = {10.1016/j.tjpad.2026.100562},
  pmid    = {41936348},
  url     = {https://doi.org/10.1016/j.tjpad.2026.100562}
}

@article{ancidoni2021-33952306,
  author  = {Ancidoni, Antonio and Bacigalupo, Ilaria and Remoli, Giulia and Lacorte, Eleonora and Piscopo, Paola and Sarti, Giulia and Corbo, Massimo and Vanacore, Nicola and others},
  title   = {{Anticancer drugs repurposed for Alzheimer's disease: a systematic review}},
  journal = {Alzheimer's research \& therapy},
  year    = {2021},
  doi     = {10.1186/s13195-021-00831-6},
  pmid    = {33952306},
  url     = {https://doi.org/10.1186/s13195-021-00831-6}
}

@article{arroyopacheco2025-39638097,
  author  = {Arroyo-Pacheco, N. and Sarmiento-Blanco, S. and Vergara-Cadavid, G. and Castro-Leones, M. and Contreras-Puentes, N.},
  title   = {{Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis}},
  journal = {Ageing research reviews},
  year    = {2025},
  doi     = {10.1016/j.arr.2024.102620},
  pmid    = {39638097},
  url     = {https://doi.org/10.1016/j.arr.2024.102620}
}

@article{andreasen2015-25789616,
  author  = {Andreasen, N. and Simeoni, M. and Ostlund, H. and Lisjo, P. I. and Fladby, T. and Loercher, A. E. and Byrne, G. J. and Murray, F. and others},
  title   = {{First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study}},
  journal = {PloS one},
  year    = {2015},
  doi     = {10.1371/journal.pone.0098153},
  pmid    = {25789616},
  url     = {https://doi.org/10.1371/journal.pone.0098153}
}

@article{wang2025-40619285,
  author  = {Wang, Hong and Nery, Emel Serap Monkul and Ardayfio, Paul and Khanna, Rashna and Svaldi, Diana Otero and Shcherbinin, Sergey and Xu, Wen and Andersen, Scott W and others},
  title   = {{The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100266},
  pmid    = {40619285},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100266}
}

@article{wang2022-35320578,
  author  = {Wang, D. and Kowalewski, E. K. and Koch, G.},
  title   = {{Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease}},
  journal = {Therapeutic innovation \& regulatory science},
  year    = {2022},
  doi     = {10.1007/s43441-022-00390-4},
  pmid    = {35320578},
  url     = {https://doi.org/10.1007/s43441-022-00390-4}
}